La cadena de opciones muestra datos clave de las opciones de acciones de Nanoviricides a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Nanoviricides..

Nanoviricides (AMEX:NNVC) Bolsa, Cadena de Opciones

Nanoviricides

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides Inc

News

Press Releases

NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention

NanoViricides Measles Drug Development Animal Study is Imminent

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

MRNA

NNVC

REGN

SMMT

VRTX

Abpro Hldgs

Azitra

BioAtla

Curis

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Edesa Biotech

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Evaxion

FibroBiologics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

Kairos Pharma

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lisata Therapeutics

Moleculin Biotech

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Passage Bio

Portage Biotech

Q32 Bio

Rallybio

Rein Therapeutics

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

EF Hutton

Cute,Little,Girl,Lying,In,Hospital,Bed,With,Teddy,Bear

Biotech

General

NanoViricides (NASDAQ: NNVC) Hits Key Milestones For Its Virus-Fighting Drug Candidate NV-387 In 2023; More To Come This Year

Comments

Nanoviricides

Nanoviricides (NNVC) Opciones

Nanoviricides (AMEX:NNVC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL